China’s NMPA authorized Changchun Genescience to begin clinical trials of Gensci‑136, a dual APRIL/BAFF antagonist for immunoglobulin A nephropathy (IgAN). The clearance enables the company to move a biologic candidate targeting B‑cell survival pathways into patients with a kidney disease that has limited therapeutic options. In the U.S., CSPC Pharmaceutical Group obtained FDA IND approval for SYH‑2082, a long‑acting GLP‑1/GIP dual‑biased agonist peptide for weight management in people with obesity or overweight and comorbidity. Both regulatory steps indicate continued global activity in immunology and metabolic therapy development and create near‑term clinical milestones for investors and program teams.